Evaluating the Usability of the Product Kinder System Trial, Home Based Hormone for In-Vitro Fertilization (IVF) Monitoring System.

Planet Innovation

Status: Enrolling

Conditions: Fertility Disorders

Treatments: Device: Kinder

Study type: Observational

Funder types: Industry

Identifiers

NCT05634850

470_1036

Details and patient eligibility

About

In-vitro fertilisation (IVF) treatment involves women undergoing hormone stimulation (drug dosing) to produce more oocytes (eggs) to increase their chances of fertilisation. The information that IVF clinicians currently collect on a woman's hormonal response to IVF drug dosing comes from in-clinic blood testing. This requires patients to make a visit to the IVF clinic every few days to have the blood samples taken. The blood is then analysed in a laboratory for the hormone levels and the results are then sent back to the clinic. This monitoring process of frequent onsite visits and blood draws can often be quite inconvenient and disruptive for patients.

This observational study will assess a non-invasive in vitro diagnostic (IVD) device for measuring the common fertility hormones in urine. The test system is for use by both healthcare professionals in a clinical setting and nonprofessionals in a home care setting under the guidance of a health care professional. This study will provide pilot data on the usability of the IVD device from the intended end users as well as the correlation of urinary metabolite levels as measured by the IVD device and the serum concentration as measured by blood analysers.

Enrollment: 25 estimated patients

Sex: Female

Ages: 30 to 40 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Women undergoing controlled ovarian stimulation treatment
• 30 to 40 years old (inclusive)
• Willingness to comply with study procedures for collection and testing of urine

Exclusion criteria

• Illiterate in English
• No access to smart phone that is compatible with App and/or is not connected to the internet
• Patients who are diabetic (Type I and Type II), have insulin resistance or a renal/liver disorder
• Patients who have taken oral contraceptives up to 4 days before the first stimulation day of the cycle